Y
Yoshikazu Inoue
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 273
Citations - 17662
Yoshikazu Inoue is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Medicine. The author has an hindex of 48, co-authored 233 publications receiving 12648 citations. Previous affiliations of Yoshikazu Inoue include Niigata University.
Papers
More filters
Proceedings ArticleDOI
Multicenter International Lymphangioleiomyomatosis Efficacy And Safety Of Sirolimus (MILES) Trial
Francis X. McCormack,Yoshikazu Inoue,Joel Moss,Lianne G. Singer,Charlie Strange,Koh Nakata,Alan F. Barker,Jeffrey T. Chapman,Mark L. Brantly,James M. Stocks,Kevin K. Brown,Joseph P. Lynch,Hilary J. Goldberg,Lisa R. Young,Brent W. Kinder,Eugene J. Sullivan,Thomas V. Colby,Roy T. McKay,Marsha M. Cohen,Leslie L. Korbee,Angelo M. Taveira-DaSilva,Hye-Seung Lee,Jeffrey P. Krischer,Bruce C. Trapnell +23 more
Journal ArticleDOI
Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial
Toru Arai,Hiroshi Kida,Yoshitaka Ogata,Satoshi Marumo,Hiroto Matsuoka,Iwao Gohma,Suguru Yamamoto,Masahide Mori,Chikatoshi Sugimoto,Kazunobu Tachibana,Masanori Akira,Yoshikazu Inoue +11 more
TL;DR: Treatment with rhTM might improve survival in AE-IIP cases with poor prognoses, and a prognostic scoring system was developed using two significant prognostic factors, higher FDP/d-dimer at AE and prednisolone therapy before AE, with 3 and 2 points assigned for each parameter, respectively.
Proceedings ArticleDOI
Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial
Kevin R. Flaherty,Athol U. Wells,Vincent Cottin,Anand Devaraj,Yoshikazu Inoue,Luca Richeldi,Simon L.F. Walsh,Martin Kolb,Dirk Koschel,Teng Moua,Susanne Stowasser,Rainer-Georg Goeldner,Rozsa Schlenker-Herceg,Kevin K. Brown +13 more
TL;DR: In the INBUILD trial, nintedanib slowed the progression of ILD in patients with fibrosing ILD and a progressive phenotype and the rate of decline in FVC over 52 weeks versus placebo.
Journal ArticleDOI
Left Vocal Cord Paralysis in Idiopathic Pleuroparenchymal Fibroelastosis: A Case Report
TL;DR: In this article , the authors presented an unusual case of idiopathic pleuroparenchymal fibroelastosis with left vocal cord paralysis that developed repeated aspiration pneumonia, and two mechanisms can be proposed: fibrous adhesion of the recurrent laryngeal nerve to the chest wall can cause stretching of the nerve.
Journal Article
[An autopsy case of gastric cancer presenting as acute respiratory failure due to pulmonary tumor thrombotic microangiopathy with concomitant high serum level of vascular endothelial growth factor-D].
TL;DR: Although there was no evidence of thrombus in the central portion of the pulmonary artery or deep veins of the lower limbs, the patient's respiratory insufficiency rapidly progressed and he died and his postmortem examination revealed widespread gastric cancer and tumor emboli in the pulmonary arterioles.